Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • China vaccine scandal...

    China vaccine scandal ripples through domestic market, threatens global push

    Written by Ruby Khatun Khatun Published On 2018-07-24T09:45:52+05:30  |  Updated On 16 Aug 2021 4:30 PM IST

    SHANGHAI: A vaccine scandal in China, which has hit a nerve in the country and prompted quick reactions from leaders in Beijing, is sending ripples across the wider domestic drug market while threatening to dent Chinese ambitions to play a larger global role.


    Shares in Chinese vaccine makers and biotech firms fell across the board on Monday after Premier Li Keqiang slammed Changsheng Biotechnology Co for having crossed a moral red line and called for swift action.

    The case erupted a week ago when Changsheng was found to have violated standards in making rabies vaccine.

    While there have been no apparent reports of people being harmed by the vaccine or having contracted rabies after receiving it, the regulator has already ordered Changsheng to halt production and recall all its vaccines.

    The case has gone viral in China, where sensitivity over food and drug safety is extremely high after a series of scandals over the last decade. Changsheng's shares, which have lost 40 percent since mid-July, were suspended on Monday.

    The scandal has sparked anger on social media and dealt a blow to China's drug regulator, which has been struggling to clean up the world's second-biggest drug industry and promote domestically made vaccines.

    It is also a setback for the country given it is looking to play a bigger role globally in the production and export of vaccines and other medicines.

    In a statement posted on the government's website late on Sunday, Premier Li called for an immediate investigation and urged severe punishment for the companies and people implicated. He added the public needed clear information.

    "We will resolutely crack down on illegal and criminal acts that endanger the safety of peoples' lives, resolutely punish lawbreakers according to the law, and resolutely and severely criticise dereliction of duty in supervision," he said.

    The China Food and Drug Administration said in a statement that its investigation had found that Changsheng fabricated production records and product inspection records, and arbitrarily changed process parameters and equipment, in "serious violations" of the law.

    PUBLIC HEALTH CRISIS

    Changsheng said in a regulatory filing that the suspension of its rabies vaccine production would have a significant impact on its finances and that some regional disease control agencies had suspended some of its other vaccines.

    An editorial on Monday in the China Daily warned the case could become a public health crisis if it is not handled "in a reasonable and transparent manner".

    "The government needs to act as soon as possible to let the public know it is resolved to address the issue and will punish any wrongdoers without mercy," it said.

    Late on Sunday, the state news agency Xinhua ran an editorial calling for strict punishment for any violations, big or small, in the vaccine industry and for regulators to close loopholes and tighten oversight of the industry.

    The China Securities News also weighed in, saying listed companies have a duty to the public and to conduct business with integrity.

    "Cases like Changsheng Biotechnology, where laws and regulations are ignored and internal controls exist only in name bring a painful price," it said.

    State media have said Changsheng made a public apology and recalled all their rabies vaccine available on the market. ($1 = 6.7659 Chinese yuan)

    (Reporting by John Ruwitch and Adam Jourdan; Editing by Himani Sarkar)

    Beijingbiotech firmsChangsheng BiotechnologychinaChina Food and Drug AdministrationChinese vaccinedomestic marketglobal pushinspectioninvestigationPremier Li Keqiangrabiesripplesscandalvaccine
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok